Syntr Health Technologies Inc., an Irvine medical device startup based at University Lab Partners at the UCI Research Park, is raising $10 million to hire a sales team and focus on marketing this year, in preparation for expanding in 2024.
The company’s fat processing machine, the SyntrFuge System, yields injectables taken from patients’ own fat tissue which can be applied to various cosmetic procedures, from facial fat transer and wrinkle reduction to breast cancer reconstructive surgery.
The SyntrFuge System, a single-use, disposable medical device, takes less than 10 minutes to process fat and is the only FDA-cleared automated fat microsizing system on the market, according to the company.
“The beauty of our devices is that we’re giving the doctors the ability to do this in their office rather than having to go to a surgical center,” the company’s CEO, Ahmed Zobi, said during his pitch at the Octane Aesthetics Tech Forum earlier this year.
$13M Sales in ’24
While serving as a convenient fat processing solution for physicians, Syntr’s device also offers “a much more natural outcome” for post-surgery patients than traditional synthetic fillers, which can distort a patient’s facial features, Zobi said.
The company currently counts 16 granted patents—eight domestic and eight overseas. It also has 15 pending patents, in regions such as the U.S., Canada, South Korea and Japan, among others.
Officials project the company will generate $13.2 million in revenue next year after it completes fundraising, with the goal of reaching $103 million by 2027.
2016 Founding
Syntr, which Zobi co-founded with VP Business Development Hugo Salas and VP Engineering Justin Stovner in 2016, has raised roughly $2.6 million in funding to date.
In 2021, the company announced it had raised an oversubscribed $2.2 million seed investing round to accelerate sales of the SyntrFuge System.
The firm said prior investors, angels and surgeons participated in the 2021 round.
Another one of Syntr’s co-founders, Derek Banyard, left the company in 2020 and now leads Sayenza Biosciences.
Zobi received his B.S. in Biomedical Engineering, specializing in micro and nanotechnology, from University of California, Irvine. He earned his MBA, with specializations in advanced corporate-level strategy and startup entrepreneurship, from the Quantic School of Business and Technology.
